Contact Us
.

Most-Favored-Nation (MFN) pricing is changing global pricing and launch decisions faster than most organizations can adapt. Policy headlines move quickly, but the harder work happens inside the company: aligning global pricing and revenue management, understanding how one price action can cascade through international reference pricing (IRP), and sequencing launches with US risk in mind. Turning strategy into action is where many teams get stuck. This session between Marbls Group and Model N is built to help close that gap. 

During this webinar, Ruven Eul of Marbls Group brings the strategic view of what MFN means for global pricing and how companies are responding. Michael Grosberg of Model N brings the execution view: where strategy breaks down when it reaches the data, the governance, and the systems that have to act on it. Kaberi Guha then offers a sneak peek at MFN Intelligence, a planning and forecasting capability designed to show IRP cascade exposure before a price action is taken. The session closes with a practical set of priorities for the next 90 to 180 days. 

You will learn to:

  • Spot where MFN pricing decisions stall between strategy and execution 
  • See what leading pharma companies are already doing in response 
  • Anticipate how one price change can ripple through international reference pricing, with a preview of MFN Intelligence
Ruven-Formal_Fav

Ruven Eul

Principal, Life Sciences and Chief Commercial Officer

Marbls Group

michael-grosberg

Michael Grosberg

VP, Product Management

Model N

Kaberi Guha

Kaberi Guha

Staff Product Manager, Global Products

Model N